ArticleAnnals of surgical oncology2016
Mixed Adeno-neuroendocrine Carcinoma: An Aggressive Clinical Entity.
Article in Annals of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Mixed epithelial endocrine neoplasms of the colon and rectum - An evolution over time: A systematic review.World journal of gastroenterology · 2020Pooled it
- Rapid Progression of Primary Hepatic Neuroendocrine Carcinoma: A Case Report Demonstrating Drastic Oncological Behavior.The American journal of case reports · 2025Article
- Oligometastatic Mixed Neuroendocrine Adenocarcinoma of the Esophago-Gastric Junction: A Case of Successful Multidisciplinary Management, the Lessons Learnt and Review of the Literature.Journal of clinical medicine · 2025Article
- Mixed neuroendocrine and adenocarcinoma of gastrointestinal tract: A complex diagnosis and therapeutic challenge.World journal of gastrointestinal oncology · 2024Article
- Mixed neuroendocrine non-neuroendocrine neoplasms in gastroenteropancreatic tract.World journal of gastrointestinal oncology · 2024Review
- Gastric mixed neuroendocrine non-neuroendocrine neoplasms.Frontiers in oncology · 2024Review
- Collision tumor of the cecum and ileocecal valve composed of mucinous adenocarcinoma and neuroendocrine tumor: a case report.AME case reports · 2024Article
- Mixed adenoneuroendocrine carcinoma originating from the appendix and colorectum: a comparative analysis of a large population-based database.Techniques in coloproctology · 2023Article
- Incidence, survival, and prognostic factors for patients with gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms: a SEER population-based study.Journal of cancer research and clinical oncology · 2023Article
- Discussion on the benefits of different treatment strategies in elderly and non-elderly patients with appendix MiNEN: a retrospective study based on SEER database.International journal of colorectal disease · 2023Article
- Review
- An Update on the Management of Mixed Neuroendocrine-Non-neuroendocrine Neoplasms (MiNEN).Current treatment options in oncology · 2022Review
- Mixed neuroendocrine-nonneuroendocrine neoplasm of the ampulla: Four case reports.World journal of clinical cases · 2022Article
- The Landmark Series: Appendiceal Primary Peritoneal Surface Malignancy.Annals of surgical oncology · 2022Review
- Goblet Cell Adenocarcinoma of the Appendix: A Systematic Review and Incidence and Survival of 1,225 Cases From an English Cancer Registry.Frontiers in oncology · 2022Article
- Mixed adenoneuroendocrine carcinomas of stomach and ampulla of vater after curative-intent resection: a single center cases series.BMC gastroenterology · 2021Article
- Chemotherapy in the treatment of different histological types of appendiceal cancers: a SEER based study.BMC cancer · 2021Article
- Palatine tonsil metastasis of cecal mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN): A unique case.Clinical case reports · 2021Article
- Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasm.Cancer medicine · 2021Article
- Diagnosis and Treatment of Primary Tumors of the Appendix: a Critical Review.Journal of gastrointestinal cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMixed adeno-neuroendocrine carcinoma (MANEC) is a rare pathologic diagnosis recently defined by the World Health Organization in 2010. Due to poor understanding of MANEC as a clinical entity, there is significant variation in the management of these patients. The purpose of our study was to characterize MANEC to develop evidence-based treatment strategies.
methodsThe Ohio State University patient database was queried for the diagnosis of MANEC and 46 patients were identified. For comparison, the database also was queried for goblet cell carcinoid (GCC) of the appendix, signet ring cell carcinoma, and carcinoid/neuroendocrine tumor of the appendix. Charts were then retrospectively reviewed for clinicopathologic characteristics, patient treatment, and survival data.
resultsThe mean age of diagnosis of MANEC was 54 years. Eighty-seven percent of MANEC arose from the appendix, with 28 % of patients undergoing appendectomy and 35 % undergoing right hemicolectomy as their index operation. Immunohistochemical staining was positive for chromogranin (82 %), synaptophysin (97 %), and CD56 (67 %). Sixty-seven percent of patients presented with stage IV disease and 41 % had nodal metastases. Overall survival was 4.1 years, which was statistically significantly different (p ≤ 0.05) compared with carcinoid tumors (13.4 years), GCC (15.4 years), and signet ring carcinoma (2.2 years).
conclusionsMANEC is a more aggressive clinical entity than both GCC of the appendix and carcinoid/neuroendocrine tumors of the appendix. Based on these findings, we recommend patients with MANEC tumors undergo aggressive multidisciplinary cancer management and close surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.